Engineered bacteria for augmented in situ tumor vaccination

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• In situ tumor vaccination elicits potent systemic antitumor immune responses.
• Bacteria serve as efficient tumor-targeted delivery vehicles and potent adjuvants.
• This approach circumvents the need for tumor antigen identification and modulates the tumor microenvironment.

Purpose of the Study:

• To review recent advances in bacterial applications for in situ cancer vaccination.
• To illustrate the mechanisms of bacteria in inducing immunogenic cell death and targeted delivery.
• To comprehensively review engineering strategies for bacteria-based in situ vaccination.

Main Methods:

• Review of current literature on bacteria-based in situ cancer vaccination.
• Illustration of bacterial mechanisms as immunogenic cell death inducers and delivery platforms.
• Comprehensive review of engineering strategies: chemical modification, nanotechnology, and genetic engineering.

Main Results:

• Bacteria effectively induce tumor immunogenic cell death and act as targeted delivery platforms.
• Engineering strategies enhance the efficacy of bacteria-based in situ vaccination.
• Significant progress has been made in developing bacteria for cancer immunotherapy.

Conclusions:

• Bacteria represent a promising platform for in situ cancer vaccination.
• Engineering strategies are crucial for optimizing bacteria-based cancer vaccines.
• Further research is needed to address current challenges and explore future directions in this field.